These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 39144648)

  • 1. A Temporal Association between Regression of Pachydrusen and Use of Proprotein Convertase Subtilisin Kexin 9 Inhibitor: A Case Report.
    Chantarasorn Y; Funilkul K
    Case Rep Ophthalmol; 2024; 15(1):614-620. PubMed ID: 39144648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
    Awanami Y; Fukuda M; Nonaka Y; Takashima T; Matsumoto K; Yamasaki M; Miyazono M; Ikeda Y
    BMC Nephrol; 2017 Jul; 18(1):221. PubMed ID: 28683788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
    Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
    J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hyperlipidemia with proprotein convertase subtilisin/kexin type 9 inhibitor in a patient with nephrotic syndrome: a case report.
    Choi HS; Kim CS; Ma SK; Kim SW; Bae EH
    Ann Palliat Med; 2020 Jul; 9(4):2357-2360. PubMed ID: 32648458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-Based Prevalence and 5-Year Change of Soft Drusen, Pseudodrusen, and Pachydrusen in a Japanese Population.
    Sato-Akushichi M; Kinouchi R; Ishiko S; Hanada K; Hayashi H; Mikami D; Ono S; Yanagi Y
    Ophthalmol Sci; 2021 Dec; 1(4):100081. PubMed ID: 36246945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan.
    Lin PL; Wu YW; Lin CF; Yeh HI; Chang WT; Charng MJ; Huang PH; Lin CC; Lin TH; Lin WW; Hsieh IC; Kuo FY; Chen CP; Li YH
    J Atheroscler Thromb; 2023 Sep; 30(9):1123-1131. PubMed ID: 36418110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
    Atreya MR; Whitacre BE; Cvijanovich NZ; Bigham MT; Thomas NJ; Schwarz AJ; Weiss SL; Fitzgerald JC; Allen GL; Lutfi R; Nowak JE; Quasney MW; Shah AS; Wong HR
    Crit Care Med; 2020 Oct; 48(10):1513-1520. PubMed ID: 32769621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.
    Rikhi R; Shapiro MD
    Eur Cardiol; 2023; 18():e45. PubMed ID: 37456766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.
    Gil-Núñez A; Masjuan J; Montaner J; Castellanos M; Segura T; Cardona P; Tembl JI; Purroy F; Arenillas J; Palacio E
    Neurologia (Engl Ed); 2022 Mar; 37(2):136-150. PubMed ID: 34906541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.